EyePoint Pharmaceuticals

Press Releases

pSivida Announces 13 New Patents Issued or Allowed
Aug 29, 2016
U.S. and foreign patents for bioerodible Medidur™, new smaller needle Medidur injector and Tethadur™
Topline Results from First Phase 3 Trial of pSivida's Medidur™ Presented at ASRS Annual Meeting
Aug 15, 2016
WATERTOWN, Mass. , Aug. 15, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that Dr. Glenn J. Jaffe , Robert Machemer Professor of Ophthalmology at Duke University School of
Primary Endpoint Met in pSivida's Utilization Study of New Medidur™ Inserter with Smaller Diameter Needle
Aug 09, 2016
Results to Form Part of Planned Applications for Marketing Approvals in EU and US
pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer
Aug 03, 2016
Industry Veteran Brings Over 25 Years of Pharmaceutical and Drug Development Experience
pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for Sustained-Release Implant for Severe Knee Osteoarthritis
Aug 01, 2016
WATERTOWN, Mass. and NEW YORK , Aug. 01, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for eye diseases, and Hospital for Special Surgery (HSS), America's leading specialty hospital devoted to orthopedics and
pSivida's Medidur™ Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001)
Jul 27, 2016
Incremental Risk of Elevated IOP Relative to Control Decreases Through Last Follow-up Visit
Data Shows pSivida's Tethadur™ Provides Prolonged, Sustained Release of Avastin® With High Drug Efficacy
Jul 20, 2016
Data Presented at 2016 Annual Meeting & Exposition of the Controlled Release Society
pSivida Corp. Announces Plan to Consolidate all Research and Development in Current U.S. Facility
Jul 15, 2016
Plan to Facilitate Product Development and Reduce Operating Expenses
Investigator-Sponsored Phase 2 Study Results Show pSivida's Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve
Jul 14, 2016
Study Results Showing No Recurrence of Disease and Statistically Significant Improvement in Visual Acuity to be Published in Ophthalmology
pSivida Announces Poster and Oral Presentation on Controlled Release of Avastin® from Tethadur™ Biodegradable Matrix at the 2016 Controlled Release Society Annual Meeting
Jul 08, 2016
WATERTOWN, Mass. , July 08, 2016 (GLOBE NEWSWIRE) -- pSivida Corp (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that pSivida's Dr. Catherine Kelly will present a poster and oral presentation on "The Controlled
pSivida Announces Successful Completion of Two Preclinical Studies of Durasert™ Sustained-Release Insert Delivering Repurposed Cancer Drug to Treat Wet AMD
Jul 05, 2016
Promising Results for Potential Sustained Treatment of Wet AMD Using a TKI
pSivida Corp. Provides Company Update and Reports Third Quarter FY 2016 Results
May 05, 2016
WATERTOWN, Mass. , May 05, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its third fiscal quarter ended March 31,
pSivida CEO to Present at 2016 International Symposium of Ocular Pharmacology and Therapeutics
May 04, 2016
WATERTOWN, Mass. , May 04, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton , president and CEO, will present "Changing the Treatment Paradigm
pSivida's Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe
May 02, 2016
WATERTOWN, Mass. , May 02, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA),  a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the European Commission granted orphan medicinal product designation to Medidur™ for
pSivida Corp. Announces Third Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
Apr 27, 2016
WATERTOWN, Mass. , April 27, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the third quarter of fiscal year 2016 will be released after
pSivida to Present at the Sidoti Spring 2016 Emerging Growth Convention
Mar 24, 2016
WATERTOWN, Mass. , March 24, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the company will be presenting at the Sidoti Spring 2016 Emerging Growth Convention at
Additional Favorable Six-Month Safety Results for pSivida's Medidur™ for Posterior Uveitis
Mar 15, 2016
Small Average Increase in IOP Relative to Control Comparable Percentage Treated with Eye Drops for Elevated IOP WATERTOWN, Mass. , March 15, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye
pSivida Corp. Provides Company Update and Reports Second Quarter FY 2016 Results
Feb 08, 2016
WATERTOWN, Mass. , Feb. 08, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV), (ASX:PVA),  a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its second fiscal quarter ended
pSivida Corp Announces Second Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
Feb 01, 2016
WATERTOWN, Mass. , Feb. 01, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the second quarter of fiscal year 2016 will be released after
pSivida CEO to Present at 18th Annual Bio CEO & Investor Conference February 9
Jan 28, 2016
WATERTOWN, Mass. , Jan. 28, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drugs for treating eye diseases, today announced that Dr. Paul Ashton , President and CEO, will present at the 18 th Annual Bio CEO & Investor Conference,
Displaying 61 - 80 of 316
EyePoint Pharmaceuticals